Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. The dose of apatinib was 500 mg/d from day 4 to 24. After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m2 on day 1, calcium levofolinate 200 mg/m2 on day 1 and 2, 5-fluorouracil 400 mg/m2 intravenously and 5-fluorouracil 600 mg/m2 intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles. He took concurrently apatinib with a dose of 500mg daily from 1 to 10 days per cycle. He was confirmed as partial response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST). The level of serum alpha-fetoprotein (AFP) decreased from 60500 ng/ml to 12.7 ng/ml, and the progression free survival (PFS) time was more than eight months. It indicated that apatinib may be a superior choice for HCC patients.
Circular RNA (circRNA), a type of endogenous non-coding RNA, is a closed continuous loop of RNA with no poly(A) tail. Previously, studies have identified that circRNAs are closely associated with several cancer types. However, their function in hepatocellular carcinoma (HCC) has rarely been studied. Therefore, the aim of the current study was to screen differential circRNA expression between HCC tissues and adjacent non-cancerous tissues, and test the potential clinical value of individual circRNAs. CircRNA microarray was used to investigate global circRNA expression profiles. Attention was then focused on the top four circRNAs whose expression levels were reduced in HCC tissues as compared with non-cancerous tissues. Additionally, RNA expression was validated in 30 matched tissue samples using reverse transcription-quantitative polymerase chain reaction. The results revealed that the expression levels of hsa_circ_0078602 and hsa_circ_0018764 were consistent with microarray analysis (P<0.05). Between these two circRNAs, hsa_circ_0078602 demonstrated an association with a favorable diagnostic efficiency, with an area under the receiver operating characteristic curve of 0.787 (P<0.001). To further verify the expression level of hsa_circ_0078602, the patient sample size was increased to 79. The results supported the conclusion that circ_0078602 was downregulated in HCC tissue compared with non-cancerous tissue (P=0.015) and exhibited diagnostic potential. Notably, it was identified that a lower hsa_circ_0078602 expression level was associated with a worse prognosis among patients with HCC. In addition, it was revealed that 9.0×10−5 was the most efficient cut-off value of hsa_circ_0078602 expression to assess the outcomes of patients with HCC. The present study revealed that hsa_circ_0078602 may be a novel diagnostic biomarker of HCC and therefore have potential prognostic value.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.